BRIEF published on 11/13/2025 at 18:02, 21 days 11 hours ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 1 month 5 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 2 months 5 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 2 months 5 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 2 months 5 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 3 months 7 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 3 months 7 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 4 months 18 days ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 4 months 18 days ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 4 months 18 days ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
Published on 12/05/2025 at 02:35, 3 hours 26 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 1 minute ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 56 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 1 minute ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 30 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 10 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 35 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 46 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 50 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 1 minute ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 16 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 16 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
